ArticleFrontiers in microbiology2025
Analytical performance and standardization of four HCV RNA assays in China: an evaluation of sensitivity, precision, and genotype inclusivity.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurate, specific, and sensitive detection and quantification of hepatitis C virus (HCV) RNA are critical for diagnosing and managing HCV infections. This study evaluated and compared the performance of four commercially available HCV RNA quantification reagents using standardized serum panels, providing evidence-based insights for clinical applications. Methods: Performance metrics, including analytical sensitivity, specificity, limit of detection (LOD), precision, genotype inclusivity (GT 1-6), and linearity, were assessed using seven distinct serum panels: basic, analytical specificity, seroconversion, analytical sensitivity, precision, genotype qualification, and linearity panels. Results: All reagents demonstrated 100% analytical sensitivity and specificity (95% CI: 79.95-100), with no cross-reactivity to common interfering substances or viruses. LOD values for reagents A, B, C, and D were 25, 50, 50, and 50 IU/ml, respectively. Intra- and inter-assay coefficients of variation (CVs) for HCV genotypes 1-6 ranged from 1.48 to 4.37% and 1.74 to 4.84%, respectively. Strong linear correlations (R Conclusion: These reagents exhibit high sensitivity, specificity, precision, and accuracy for HCV genotypes 1-6, with a wide linear range, making them suitable for clinical diagnosis and monitoring of HCV infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.